文献速递肝病

基因组分析在瘦型非酒精性脂肪性肝病临床评估中的新兴作用

Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD.
PubMed 文献 · Hepatology · 2021-01-01

本文综述瘦型非酒精性脂肪性肝病(lean NAFLD)的流行病学、自然史与预后,提出结合详细临床表型与基因组分析的诊断路径,并将lean NAFLD分为内脏肥胖伴胰岛素抵抗但BMI正常型(1型)和单基因病所致肝脂肪变型(2型)。

要点

  • 瘦型NAFLD定义为BMI<25 kg/m2(亚洲人<23 kg/m2),占NAFLD患者的10–20%。
  • 诊断路径应整合临床表型与基因组分析,计算多基因风险评分并排查单基因病。

核心结论

  • 在瘦型NAFLD临床评估中整合分子诊断有助于准确诊断、可能靶向治疗并揭示新分子机制。

研究设计与样本

  • 综述,总结瘦型NAFLD的流行病学、自然史和预后数据,并提出结合临床表型与基因组分析的诊断方法。

主要发现

  • 提出lean NAFLD两个亚型:1型为内脏肥胖和胰岛素抵抗但BMI正常;2型为已知或未知单基因病所致肝脂肪变。

关键数值与推荐

  • 瘦型定义:BMI<25 kg/m2,亚洲人<23 kg/m2。
  • 瘦型NAFLD占NAFLD的10–20%。

临床怎么用

  • 对瘦型NAFLD患者,临床评估应结合详细表型与基因组分析,计算NAFLD多基因风险评分并排查单基因病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Whereas the rising prevalence of nonalcoholic fatty liver disease (NAFLD) is closely related with the global obesity epidemic, up to 10–20% of individuals with NAFLD are lean as defined by a body mass index of < 25 kg/m2, or < 23 kg/m2 in Asians. This entity designated as “lean NAFLD” is estimated to affect 8 to 10 million individuals in the United States alone. Here, we review the emerging data on the epidemiology, natural history and prognosis of lean NAFLD and put forward a diagnostic approach that combines detailed clinical phenotyping with genomic analysis. We propose two subtypes of lean NAFLD referred to as type 1: individuals with visceral adiposity and insulin resistance but normal BMI; and type 2: lean individuals with hepatic steatosis secondary to a known or unknown monogenic disease. We envision that incorporation of genomic analysis in the diagnostic algorithm of lean patients with NAFLD will elucidate the contribution of common genetic variants through the calculation of NAFLD polygenic risk score and also characterize the diverse array of rare monogenic diseases that can lead to triglyceride accumulation in the cytoplasm of hepatocytes. Collectively, the integration of a molecular diagnosis in the clinical evaluation of patients with lean NAFLD will provide an accurate diagnosis, with possible targeted therapies and may uncover novel molecular mechanisms with potential broader therapeutic implications.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Vilarinho S, Ajmera V, Zheng M, et al. Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD. Hepatology. 2021. PMID: 34233030. doi:10.1002/hep.32047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。